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Purpose: The aim of this study was to investigate the prognosis of papillary thy-
roid carcinoma (PTC) patients according to different pathologic grades of lympho-
cytic thyroiditis (LT). Materials and Methods: This study included 144 PTC pa-
tients who underwent total thyroidectomy with radioactive iodine remnant ablation 
therapy. Pathologic grades of LT were separated at two points, chronic lymphocyt-
ic thyroiditis (CLT) and Hashimoto thyroiditis (HT). Patients were divided into 
two groupings according to the presence of the diseases (Grouping 1; patients with 
CLT or HT and without CLT or HT, Grouping 2; patients with HT and without 
HT). The groupings were compared according to recurrence, clinicopathologic and 
ultrasound (US) characteristics, and disease free survival. Results: Of 144 patients, 
41 had CLT and 19 had HT. There were 10 patients (6.9%) with tumor recurrence. 
In both groupings, the presence of calcification was more frequently associated 
with patients with LT (p=0.041 and 0.047, respectively). In Grouping 2, the mean 
age at diagnosis was older in patients without HT compared to patients with HT 
(p=0.032). On multivariate analysis, the presence of LT was not an independent 
predictor of recurrence in both groupings. For both groupings, pathologic tumor 
size and taller than wide shape on US were independent predictors of recurrence. 
The presence of LT in PTC patients did not affect recurrence. Conclusion: There 
was no relationship between PTC prognosis and different grades of LT. Pathologic 
tumor size and taller than wide shape on ultrasound were independent predictors 
of PTC recurrence regardless of concurrent LT.
Key Words:   Lymphocytic thyroiditis, papillary thyroid carcinoma, pathological 
grade, ultrasonography, prognostic factor
INTRODUCTION
Hashimoto thyroiditis (HT) is a common finding in resected thyroid specimens.1 
However, even though other aspects of HT have been extensively studied, there is 
still controversy on whether patients with papillary thyroid carcinoma (PTC) and 
concurrent HT are associated with favorable outcomes.2-10 Whereas several reports 
concluded that better prognosis was shown in the patients with the two diseases at 
the same time,4,6,7,11 the other reports conclude that HT was no significant prognos-
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categorized as iso- or hypoechogenicity (which was defined 
as iso- or hypoechogenic compared to the normal thyroid 
gland) and marked hypoechogenicity (which was defined as 
hypoechogenic compared to the strap muscle). The margin 
was categorized as well defined and not well defined. Cal-
cification was categorized as presence of calcification and 
without calcification. The shape was described as wider 
than tall (which was defined as a ratio of the transverse di-
ameter to the anteroposterior diameter of <1) and taller than 
wide (which was defined as a ratio of the transverse diame-
ter to the anteroposterior diameter of  ≥1).
Histopathologic analysis
All surgical specimens of the 144 patients were re-evaluated 
by one pathologist (K.H.K.). Background thyroid pathology 
was evaluated based upon the presence of lymphocytic thy-
roiditis (LT). In this study, LT included both CLT and HT. 
CLT was defined with the histologic features of the presence 
of diffuse lymphocytic infiltrate, oxyphilic cells, and forma-
tion of lymphoid follicles with germinal centers. HT was de-
fined with the histologic features of diffuse lymphocytic thy-
roiditis with follicular atrophy, diffuse destruction of thyroid 
follicles, fibrosis, and follicular cell regeneration.12 Peritu-
moral inflammatory response was not considered as lym-
phocytic thyroiditis change.
Postoperative management and follow-up
Patients were followed every six months in the first three 
years after surgery. Afterwards, follow-up evaluations took 
place every twelve months. Recurrence was defined with 
elevated serum Tg, uptake on 131I whole body scan, or cyto-
logic confirmation of PTC. US-guided fine needle aspiration 
(US-FNA) was performed to obtain cytopathologic speci-
mens to confirm recurrence. Patients with no detectable Tg, 
no regional or distant metastasis on imaging studies, no evi-
dence of regional recurrence on neck US, and benign cytol-
ogy results after US-FNA were classified as the no recur-
rence group. 
Data and statistical analysis
In this study, LT was divided into CLT and HT for analysis. 
Two different groupings were formed by two different refer-
ence points (CLT and HT) of LT. For Grouping 1, subjects 
were divided into PTCs without LT (including both CLT 
and HT) and PTCs with LT. For Grouping 2, subjects were 
divided into PTCs without HT and PTCs with HT. We used 
the independent t-test for continuous variables and the chi-
tic factor predicting the outcome of PTC patients.2,3
Autoimmune thyroiditis, of which the pathologic hall-
mark is lymphocytic infiltration, can show a certain patho-
logic spectrum from lymphocytic infiltration only (chronic 
lymphocytic thyroiditis, CLT) to progressive loss of thyroid 
follicular cells, a concomitant replacement of the gland by 
lymphocytes, and the formation of germinal centers associ-
ated with fibrosis (HT).12 As the disease progresses the cel-
lular infiltrate and the fibroblastic tissue increase, resulting 
in the disorganization and destruction of thyroid tissue.13 
Therefore, this certain spectrum of pathologic features may 
affect the prognosis of PTC patients in different ways. To 
the best of our knowledge, no reports have compared CLT 
and HT with the prognosis of PTC. Therefore, our goal was 
to investigate the prognosis of PTC patients according to 
the presence of CLT or HT. 
MATERIALS AND METHODS
　　　
The Institutional Review Board of Severance Hospital ap-
proved this retrospective observational study and required 
neither patient approval nor informed consent for review of 
patients’ images and medical records. 
Study population
Between April 2003 and December 2004, preoperative ul-
trasound (US) and pathologic slides were both found avail-
able for 356 PTC patients. 119 patients were excluded from 
this study as they had another coexisting primary site of can-
cer (n=15), previous surgical history of the thyroid gland 
(n=14), or follow up loss in 5 years (n=90). For the survival 
analysis, patients who underwent the same therapy had to be 
selected for the study. Therefore, among the remaining 237 
patients who underwent both total thyroidectomy with ra-
dioactive iodine remnant ablation were selected, making a 
total of 144 patients for the study population. 
Ultrasonographic features
US images were obtained using 5--12-MHz linear transduc-
ers (HDI 5000 and IU-22, respectively; Philips, Bothell, WA, 
USA). All US examinations were reviewed on a GE Centric-
ity PACS workstation (GE Healthcare, Milwaukee, WI, 
USA) by one radiologist (K.J.Y.). US features of thyroid can-
cers were described by composition, echogenicity, margin, 
calcification, and shape.14 The internal composition was clas-
sified as solid and mixed. The echogenicity of a nodule was 
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square test for categorical variables to compare clinicopath-
ologic characteristics among the two different groupings. 
Disease free survivals were calculated by the Kaplan-
Meier method and the log-rank sum test according to the 
presence of LT (including both CLT and HT) or HT. Uni-
variate and multivariate Cox proportional hazard regression 
models were used to determine the association between 
clinicopathologic parameters and recurrence during the fol-
low-up period in the two groupings. A two-tailed p value 
<0.05 was considered statistically significant. Statistical 
analysis was performed using SAS software (version 9.1.3; 




Clinicopathologic characteristics of the included 144 pa-
tients are summarized in Table 1. The follow-up period 
ranged from 38 to 92 months (mean, 68.9±8.1 months). Of 
the 144 patients, 41 had CLT and 19 had HT. There were 
10 patients (6.9%) with tumor recurrence. Among the 10 
patients with recurrence, one had CLT and two had HT. Ta-
Table 1. Clinicopathologic Characteristics in 144 Patients 





    Age at diagnosis (yrs) 47.9±10.8 (25--75)
    Groups (<45/≥45 yrs) 58/86
Gender 
    Female, n (%) 133 (92.4) 
    Male, n (%) 11 (7.6)
Primary tumor
    Pathologic size (mm) 9.2±6.4 (2--40)
    Multifocality, n (%)   39 (27.1)
    Extrathyroidal extension, n (%)   35 (24.3)
Nodal involvement
    Central compartment, n (%)   61 (42.4)
    Lateral compartment, n (%)   7 (4.9)
Recurrence (%) 10 (6.9)
    Lateral lymph node 6
    Biochemical 3
    Operation bed 1
    Contralateral thyroid gland 1
n, number.
Table 2. Difference in Clinicopathologic and Ultrasound Characteristics between PTC Patients with or without CLT or HT 
 Without LT (n=103) With LT (n=41) p value Without HT (n=125) With HT (n=19) p value
Male gender    11 (10.7)      0 (0.0) 0.034    11 (8.8)      0 (0.0) 0.360 
Mean age at diagnosis (yrs) 48.9 (25--75, 10.8) 45.4 (28--69, 10.4) 0.078 48.6 (25--75, 107) 43.0 (28--65, 10.4) 0.032
Mean tumor size (mm)   9.1 (2--40, 6.4)   9.3 (3--35, 6.6) 0.838   9.3 (2--40, 6.7)   8.6 (3--15, 3.8) 0.698
Multiplicity (n =39)    28 (27.2)    11 (26.8) 1.000    32 (25.6)      7 (36.8) 0.405 
Central LN metastasis (n=61)    39 (37.9)    22 (53.7) 0.095    50 (40.0)    11 (57.9) 0.212 
Lateral LN metastasis (n=7)      5 (4.9)      2 (4.9) 1.000      6 (4.8)      1 (5.3) 1.000 
Extrathyroidal extension (n=35)    24 (23.3)    11 (26.8) 0.671    31 (24.8)      4 (21.1) 1.000 
Recurrence (n=31)    25 (24.3)    26 (63.4) 0.264    28 (22.4)      3 (15.8) 0.765 
US features 
    Composition 0.675 1.000 
        Solid (n=138)    98 (95.1)    40 (97.6)  119 (95.2)    19 (100.0)
        Mixed (n=6)      5 (4.9)      1 (2.4)      6 (4.8)      0 (0.0)
    Echogenicity 1.000 0.528 
        Iso & hyopoechogenicity (n=117)    84 (81.6)    33 (80.5)  100 (80.0)    17 (89.5)
        Marked hypoechogenicity (n=27)    19 (18.4)      8 (19.5)    25 (20.0)      2 (10.5)
    Margin 0.487 1.000 
        Well defined margin (n=27)    21 (20.4)      6 (14.6)    24 (19.2)      3 (15.8)
        Not well defined margin (n=117)    82 (79.6)    35 (85.4)  101 (80.8)    16 (84.2)
    Calcifications 0.041 0.047 
        Presence of calcifications (n=82)    53 (51.5)    29 (70.7)    67 (53.6)    15 (78.9)
        No calcification (n=62)    50 (48.5)    12 (29.3)    58 (46.4)      4 (21.1)
    Shape 0.185 0.800 
        Taller than wide (n=90)    68 (66.0)    22 (53.7)    79 (63.2)    11 (57.9)
        Wider than tall (n=54)    35 (34.0)    19 (46.3)    46 (36.8)      8 (42.1)
PTC, papillary thyroid carcinoma; CLT, chronic lymphocytic thyroiditis; HT, Hashimoto thyroiditis; LT, lymphocytic thyroiditis; LN, lymph node; US, ultrasound.
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ther LT nor HT was an independent predictor of recurrence. 
Pathologic tumor size and taller than wide shape on US were 
independent predictors of recurrence in both groupings.
DISCUSSION
Lymphocytic thyroiditis has a certain pathologic spectrum 
with various degrees of inflammatory change with lympho-
cytic infiltration.15 Although a number of investigators have 
classified LT into several types according to different de-
grees of lymphocytic infiltration, epithelial changes, and fi-
brosis (Table 5),15-21 most pathologists have used CLT and 
ble 2 shows the clinicopathologic and US characteristics of 
the two groupings. CLT or HT was only found in patients 
of the female gender. In Grouping 2, the mean age at diag-
nosis was older in patients without HT (p=0.032). In both 
groupings, the presence of calcification was more frequent-
ly associated with patients with LT (including both CLT 
and HT) or HT (p=0.041 and 0.047, respectively). 
The Kaplan-Meier analysis demonstrated that the presence 
of LT (both CLT and HT) or HT in PTC patients did not alter 
the probability of recurrence developing (Fig. 1). To identify 
predictive factors of recurrence, a Cox proportional hazard 
model was created. Univariate and multivariate analysis re-
sults are listed in Table 3 and 4. On multivariate analysis, nei-
Fig. 1. Disease free survivals in patients with or without lymphocytic thyroiditis (LT, including both chronic lymphocytic thyroiditis and Hashimoto thyroiditis) 
(A) and Hashimoto thyroiditis (HT) (B). Log-rank test p-value of A and B is 0.880 and 0.459, respectively. 
Table 3. Univariate and Multivariate Predictors of Recurrence When LT Including Both CLT and HT Is Considered as One of 
the Clinicopathologic Parameters
Clinicopathologic parameter
Univariate analysis Multivariate analysis
Hazard ratio (95% CI) p value Hazard ratio (95% CI) p value
Male gender 1.264 (0.160, 9.977) 0.824 2.887 (0.270, 30.848) 0.390
Mean age at diagnosis 0.986 (0.930, 1.046) 0.639 0.962 (0.899, 1.029) 0.257
Mean tumor size (mm) 1.085 (1.030, 1.143) 0.002 1.251 (1.075, 1.454) 0.004
Multiplicity 1.856 (0.524, 6.579) 0.338 2.424 (0.479, 12.261) 0.284
Central LN metastasis 1.784 (0.501, 6.347) 0.372 1.322 (0.286, 6.118) 0.721
Lateral LN metastasis 2.760 (0.344, 22.144) 0.340 5.992 (0.165, 217.500) 0.329
Extrathyroidal extension 3.040 (0.878, 10.520) 0.079 1.776 (0.426, 7.414) 0.431
LT including CLT and HT 1.110 (0.287, 4.295) 0.880 1.145 (0.242, 5.411) 0.865
US features 
    Solid composition 0.415 (0.052, 3.278) 0.404 65.041 (0.351, 12049.760) 0.117
    Hypoechogenicity NA NA
    Not well defined margin 2.089 (0.265, 16.489) 0.485 3.229 (0.093, 112.626) 0.518
    Presence of calcifications 3.030 (0.643, 14.269) 0.161 1.642 (0.295, 9.145) 0.572
    Taller than wide shape 1.499 (0.387, 5.809) 0.558 10.013 (1.133, 88.484) 0.038





























0 020 2040 4060 6080 80100 100120 120
A B
  Without LT
  With LT
         Without LT-censored
         With LT-censored
  Without LT
  With LT
         Without LT-censored
         With LT-censored
Lymphocytic Infiltration and Thyroid Carcinoma
Yonsei Med J   http://www.eymj.org   Volume 55   Number 4   July 2014 883
cells.24 Although its nature remains uncertain, studies re-
garding the relationship between CLT or HT and PTC have 
been reported. As HT patients showed a higher incidence of 
thyroid carcinoma, HT was thought to be a predisposing 
factor in the development of thyroid carcinoma.25 However, 
there was a report showing that the pathogenesis of PTC it-
self stimulates lymphocytic infiltration and the autoimmune 
mechanism was suggested as a result of malignant patho-
genesis rather than as a premalignant factor.26 In fact, CLT 
and HT have been reported to be favorable factors in the 
prognosis of PTC,4,7,17,27 although the issue remains some-
what controversial.2,3 The presence of CLT or HT in PTC 
patients has been related to lower T stage, less extrathyroi-
HT. CLT is defined when histologic characteristics meet the 
following conditions; presence of diffuse lymphocytic infil-
trate, oxyphilic cells, and the formation of lymphoid folli-
cles or reactive germinal centers.8 HT has been differentiat-
ed from CLT and is defined when histologic characteristics 
meet the following additional conditions along with the 
characteristics of CLT; presence of Hurthle cells and vary-
ing degree of acini atrophy.22 
The nature association between LT and PTC is still un-
certain. A molecular study concluded that multiple occult 
tumors exist in HT at high frequency.23 Some studies sug-
gested that chronic thyroiditis will induce malignant trans-
formation by enhancing mitosis and proliferation of thyroid 
Table 4. Univariate and Multivariate Predictors of Recurrence When HT Is Considered as One of the Clinicopathologic Pa-
rameters
Clinicopathologic parameter
Univariate analysis Multivariate analysis
Hazard ratio (95% CI) p value Hazard ratio (95% CI) p value
Male gender 1.264 (0.160, 9.977) 0.824 2.795 (0.280, 27.929) 0.382
Mean age at diagnosis 0.986 (0.930, 1.046) 0.639 0.963 (0.899, 1.031) 0.276
Mean tumor size (mm) 1.085 (1.030, 1.143) 0.002 1.249 (1.075, 1.451) 0.004
Multiplicity 1.856 (0.524, 6.579) 0.338 2.374 (0.479, 11.765) 0.290
Central LN metastasis 1.784 (0.501, 6.347) 0.372 1.316 (0.278, 6.232) 0.729
Lateral LN metastasis 2.760 (0.344, 22.144) 0.340 6.019 (0.168, 215.656) 0.326
Extrathyroidal extension 3.040 (0.878, 10.520) 0.079 1.801 (0.435, 7.458) 0.417
Hashimoto thyroiditis 1.783 (0.378, 8.407) 0.465   1.14 (0.187, 6.948) 0.887
US features 
    Solid composition 0.415 (0.052, 3.278) 0.404 65.607 (0.358, 12025.990) 0.116
    Hypoechogenicity NA NA
    Not well defined margin 2.089 (0.265, 16.489) 0.485 3.283 (0.096, 112.225) 0.510
    Presence of calcifications 3.030 (0.643, 14.269) 0.161 1.656 (0.299, 9.160) 0.563
    Taller than wide shape 1.499 (0.387, 5.809) 0.558 9.564 (1.036, 88.266) 0.046
HT, Hashimoto thyroiditis; CI, confidence interval; LN, lymph node; US, ultrasound; NA, not applicable.
Table 5. Gradings of Lymphocytic Thyroiditis Proposed by Previous Literatures
Author
Cytological groups
Grade Lymphocytic infiltration Epithelial change (Hurthle cell metaplasia) Fibrosis
LiVolsi15   
Focal Mild to moderate Unusual Unusual
Mixed Moderate Normal to hyperplasia to metaplasia Minimal
Oxyphilic Diffuse Diffuse Diffuse
Bhatia, et al.16
0 No NA NA
1 Few NA NA
2 Moderate NA NA
3 Germinal center formation NA NA
Kebebew, et al.17
0 No NA NA
1 Scanty NA NA
2 Focally dense NA NA
3 Diffuse dense NA NA
Kumar, et al.18
1 Minimal NA NA
2 Moderate to heavy NA NA
NA, not applicable.
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there was a relatively small number of the study population 
to compare disease free survival between each group of pa-
tients. Further study is needed with larger number of patients 
in each group to obtain more profound results. 
We conclude that there was no relationship between PTC 
prognosis and different grades of LT. Pathologic tumor size 
and taller than wide shape on US were independent predic-
tors of PTC recurrence regardless of concurrent LT. 
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